{
    "Clinical Trial ID": "NCT01998906",
    "Intervention": [
        "INTERVENTION 1: ",
        "  HER2+ TC",
        "  Participants with HER2+ breast cancer received treatment as follows:",
        "  Cycles 1-3 (3-week cycles): trastuzumab 8 mg/kg, IV on Day 1 (Cycle 1 only; 6 mg/kg in Cycles 2 and 3), doxorubicin 60 mg/m^2, IV, and paclitaxel 150 mg/m^2, IV, on Day 1 followed by 2 weeks off.",
        "  Cycles 4-7 (3-week cycles): trastuzumab 6 mg/kg, IV, paclitaxel 175 mg/m^2, IV, on Day 1, followed by 2 weeks off.",
        "  Cycles 8-10 (3-week cycles): trastuzumab 6 mg/kg, IV, on Day 1 and cyclophosphamide 600 mg/m^2, IV, methotrexate 40 mg/m^2, IV, and 5-fluorouracil 600 mg/m^2, IV, (collectively CMF) on Days 1 and 8, followed by 2 weeks off.",
        "  Cycles 11-17 (3-week cycles): postoperatively, participants received trastuzumab 6 mg/kg IV on Day 1, followed by 2 weeks off for maximum of 17 overall cycles with trastuzumab. Adjuvant tamoxifen, 20 mg/day was administered for up to 5 years.",
        "INTERVENTION 2: ",
        "  HER2+ C",
        "  Participants with HER2+ breast cancer received treatment as follows:",
        "  Cycles 1-3 (3-week cycles): doxorubicin 60 mg/m^2, IV and paclitaxel 150 mg/m^2, IV, on Day 1 followed by 2 weeks off.",
        "  Cycles 4-7 (3-week cycles): paclitaxel 175 mg/m^2, IV, on Day 1, followed by 2 weeks off.",
        "  Cycles 8-10 (3-week cycles): cyclophosphamide 600 mg/m^2, IV, methotrexate 40 mg/m^2, IV, and 5-fluorouracil 600 mg/m^2, IV, on Days 1 and 8, followed by 1 week off."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  female patients, >=18 years of age, with locally advanced breast cancer.",
        "Exclusion Criteria:",
        "  previous therapy for any invasive malignancy."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Event-Free Survival (EFS) - Percentage of Participants With an Event",
        "  EFS was defined as the time between randomization and date of documented occurrence of disease recurrence or progression (local, regional, distant or contralateral) or death due to any cause.",
        "  Time frame: Baseline (BL), Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter",
        "Results 1: ",
        "  Arm/Group Title: HER2+ TC",
        "  Arm/Group Description: Participants with HER2+ breast cancer received treatment as follows:",
        "  Cycles 1-3 (3-week cycles): trastuzumab 8 mg/kg, IV on Day 1 (Cycle 1 only; 6 mg/kg in Cycles 2 and 3), doxorubicin 60 mg/m^2, IV, and paclitaxel 150 mg/m^2, IV, on Day 1 followed by 2 weeks off.",
        "  Cycles 4-7 (3-week cycles): trastuzumab 6 mg/kg, IV, paclitaxel 175 mg/m^2, IV, on Day 1, followed by 2 weeks off.",
        "  Cycles 8-10 (3-week cycles): trastuzumab 6 mg/kg, IV, on Day 1 and cyclophosphamide 600 mg/m^2, IV, methotrexate 40 mg/m^2, IV, and 5-fluorouracil 600 mg/m^2, IV, (collectively CMF) on Days 1 and 8, followed by 2 weeks off.",
        "  Cycles 11-17 (3-week cycles): postoperatively, participants received trastuzumab 6 mg/kg IV on Day 1, followed by 2 weeks off for maximum of 17 overall cycles with trastuzumab. Adjuvant tamoxifen, 20 mg/day was administered for up to 5 years.",
        "  Overall Number of Participants Analyzed: 115",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  40.0",
        "Results 2: ",
        "  Arm/Group Title: HER2+ C",
        "  Arm/Group Description: Participants with HER2+ breast cancer received treatment as follows:",
        "  Cycles 1-3 (3-week cycles): doxorubicin 60 mg/m^2, IV and paclitaxel 150 mg/m^2, IV, on Day 1 followed by 2 weeks off.",
        "  Cycles 4-7 (3-week cycles): paclitaxel 175 mg/m^2, IV, on Day 1, followed by 2 weeks off.",
        "  Cycles 8-10 (3-week cycles): cyclophosphamide 600 mg/m^2, IV, methotrexate 40 mg/m^2, IV, and 5-fluorouracil 600 mg/m^2, IV, on Days 1 and 8, followed by 1 week off.",
        "  Overall Number of Participants Analyzed: 116",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  50.9"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 18/115 (15.65%)",
        "  Febrile neutropenia * 7/115 (6.09%)",
        "  Neutropenia * 1/115 (0.87%)",
        "  Pancytopenia * 1/115 (0.87%)",
        "  Diarrhoea * 0/115 (0.00%)",
        "  Nausea * 0/115 (0.00%)",
        "  Stomatitis * 0/115 (0.00%)",
        "  Vomiting * 1/115 (0.87%)",
        "  Asthenia * 1/115 (0.87%)",
        "  Mucosal inflammation * 0/115 (0.00%)",
        "  Pyrexia * 3/115 (2.61%)",
        "  Gastrointestinal infection * 1/115 (0.87%)",
        "Adverse Events 2:",
        "  Total: 8/112 (7.14%)",
        "  Febrile neutropenia * 3/112 (2.68%)",
        "  Neutropenia * 2/112 (1.79%)",
        "  Pancytopenia * 0/112 (0.00%)",
        "  Diarrhoea * 2/112 (1.79%)",
        "  Nausea * 2/112 (1.79%)",
        "  Stomatitis * 1/112 (0.89%)",
        "  Vomiting * 1/112 (0.89%)",
        "  Asthenia * 0/112 (0.00%)",
        "  Mucosal inflammation * 1/112 (0.89%)",
        "  Pyrexia * 0/112 (0.00%)",
        "  Gastrointestinal infection * 0/112 (0.00%)"
    ]
}